Marshall Wace North America L.P. Takes Position in Syneos Health Inc (SYNH)

Marshall Wace North America L.P. bought a new stake in shares of Syneos Health Inc (NASDAQ:SYNH) in the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 340,197 shares of the company’s stock, valued at approximately $17,537,000. Marshall Wace North America L.P. owned 0.33% of Syneos Health as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. First Manhattan Co. acquired a new stake in shares of Syneos Health in the 3rd quarter worth approximately $103,000. First Trust Advisors LP acquired a new stake in shares of Syneos Health in the 2nd quarter worth approximately $241,000. Crossmark Global Holdings Inc. acquired a new stake in shares of Syneos Health in the 2nd quarter worth approximately $246,000. Janney Montgomery Scott LLC acquired a new stake in shares of Syneos Health in the 2nd quarter worth approximately $252,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Syneos Health in the 3rd quarter worth approximately $294,000.

NASDAQ SYNH opened at $47.98 on Friday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.97 and a current ratio of 0.97. Syneos Health Inc has a 12 month low of $31.10 and a 12 month high of $53.95. The company has a market capitalization of $5.08 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 1.14 and a beta of 0.97.

Syneos Health (NASDAQ:SYNH) last released its earnings results on Tuesday, November 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.17. Syneos Health had a negative net margin of 0.84% and a positive return on equity of 8.67%. The business had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.12 billion. The firm’s revenue was up 88.3% compared to the same quarter last year. On average, research analysts expect that Syneos Health Inc will post 2.47 EPS for the current fiscal year.

SYNH has been the subject of a number of research analyst reports. UBS Group initiated coverage on shares of Syneos Health in a research note on Tuesday, October 9th. They issued a “buy” rating and a $60.00 price target for the company. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a research note on Friday, November 30th. ValuEngine raised shares of Syneos Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 10th. Evercore ISI initiated coverage on shares of Syneos Health in a research note on Thursday, October 4th. They issued an “outperform” rating and a $58.00 price target for the company. Finally, KeyCorp upped their price target on shares of Syneos Health from $54.00 to $59.00 and gave the stock an “overweight” rating in a research note on Friday, August 10th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Syneos Health has an average rating of “Buy” and a consensus price target of $54.90.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/12/08/marshall-wace-north-america-l-p-takes-position-in-syneos-health-inc-synh.html.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Featured Article: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply